Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea

Ho Sup Lee, Kihyun Kim, Dok Hyun Yoon, Jinseok Kim, Soo Mee Bang, Jeong Ok Lee, Hyeon Seok Eom, Hyewon Lee, Inho Kim, Won Sik Lee, Sung Hwa Bae, Se Hyung Kim, Mark Hong Lee, Young Rok Do, Jae Hoon Lee, Junshik Hong, Ho Jin Shin, Ji Hyun Lee, Yeung Chul Mun, Chang Ki Min

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5: 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

Original languageEnglish
Article number253243
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Waldenstrom Macroglobulinemia
Chemotherapy
Korea
Drug Therapy
Survival
Republic of Korea
Survival Rate
Paraproteinemias
Proxy
Infiltration
Cytogenetics
Immunoglobulin M
Bone
B-Lymphocytes
Bone Marrow
Cells
Confidence Intervals
Neoplasms

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Lee, Ho Sup ; Kim, Kihyun ; Yoon, Dok Hyun ; Kim, Jinseok ; Bang, Soo Mee ; Lee, Jeong Ok ; Eom, Hyeon Seok ; Lee, Hyewon ; Kim, Inho ; Lee, Won Sik ; Bae, Sung Hwa ; Kim, Se Hyung ; Lee, Mark Hong ; Do, Young Rok ; Lee, Jae Hoon ; Hong, Junshik ; Shin, Ho Jin ; Lee, Ji Hyun ; Mun, Yeung Chul ; Min, Chang Ki. / Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. In: BioMed Research International. 2014 ; Vol. 2014.
@article{4ec01c8503de48699fb16d14bc1ac7f1,
title = "Clinical factors associated with response or survival after chemotherapy in patients with Waldenstr{\"o}m macroglobulinemia in Korea",
abstract = "Waldenstr{\"o}m's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5: 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9{\%} versus 52.6{\%}, P = 0.006). The 5-year overall survival rate was 62.6{\%} (95{\%} confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.",
author = "Lee, {Ho Sup} and Kihyun Kim and Yoon, {Dok Hyun} and Jinseok Kim and Bang, {Soo Mee} and Lee, {Jeong Ok} and Eom, {Hyeon Seok} and Hyewon Lee and Inho Kim and Lee, {Won Sik} and Bae, {Sung Hwa} and Kim, {Se Hyung} and Lee, {Mark Hong} and Do, {Young Rok} and Lee, {Jae Hoon} and Junshik Hong and Shin, {Ho Jin} and Lee, {Ji Hyun} and Mun, {Yeung Chul} and Min, {Chang Ki}",
year = "2014",
month = "1",
day = "1",
doi = "10.1155/2014/253243",
language = "English",
volume = "2014",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Lee, HS, Kim, K, Yoon, DH, Kim, J, Bang, SM, Lee, JO, Eom, HS, Lee, H, Kim, I, Lee, WS, Bae, SH, Kim, SH, Lee, MH, Do, YR, Lee, JH, Hong, J, Shin, HJ, Lee, JH, Mun, YC & Min, CK 2014, 'Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea', BioMed Research International, vol. 2014, 253243. https://doi.org/10.1155/2014/253243

Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. / Lee, Ho Sup; Kim, Kihyun; Yoon, Dok Hyun; Kim, Jinseok; Bang, Soo Mee; Lee, Jeong Ok; Eom, Hyeon Seok; Lee, Hyewon; Kim, Inho; Lee, Won Sik; Bae, Sung Hwa; Kim, Se Hyung; Lee, Mark Hong; Do, Young Rok; Lee, Jae Hoon; Hong, Junshik; Shin, Ho Jin; Lee, Ji Hyun; Mun, Yeung Chul; Min, Chang Ki.

In: BioMed Research International, Vol. 2014, 253243, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea

AU - Lee, Ho Sup

AU - Kim, Kihyun

AU - Yoon, Dok Hyun

AU - Kim, Jinseok

AU - Bang, Soo Mee

AU - Lee, Jeong Ok

AU - Eom, Hyeon Seok

AU - Lee, Hyewon

AU - Kim, Inho

AU - Lee, Won Sik

AU - Bae, Sung Hwa

AU - Kim, Se Hyung

AU - Lee, Mark Hong

AU - Do, Young Rok

AU - Lee, Jae Hoon

AU - Hong, Junshik

AU - Shin, Ho Jin

AU - Lee, Ji Hyun

AU - Mun, Yeung Chul

AU - Min, Chang Ki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5: 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

AB - Waldenström's macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all (n = 71) patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37-92 years) and male to female ratio was 5: 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%, P = 0.006). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73-111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.

UR - http://www.scopus.com/inward/record.url?scp=84903650086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903650086&partnerID=8YFLogxK

U2 - 10.1155/2014/253243

DO - 10.1155/2014/253243

M3 - Article

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 253243

ER -